- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agios Pharmaceuticals, Inc (AGIO)
Track today's live Agios (AGIO) share price, performance and key data on this page with our current NASDAQ:AGIO stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Agios share price on the NASDAQ exchange. Use the dropdown to switch exchange for the AGIO share price, head to our technical summary section, which provides analysis on Agios share price buy/sell indicators using real-time data (or discuss the Agios (AGIO) stock price today with other investors in the Agios NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:AGIO share price (ISIN: US00847X1046) to enhance your trading decisions with our free investment tools and resources.
What Is the Agios Pharmaceuticals, Inc Share Price Today?
The Agios share price today is 31.80.
What Is the Stock Symbol for Agios Pharmaceuticals, Inc
The stock symbol (or 'ticker') for Agios Pharmaceuticals, Inc is "AGIO."
What Stock Exchange Does Agios Pharmaceuticals, Inc Trade On?
Agios Pharmaceuticals, Inc is listed and trades on the NASDAQ stock exchange.
Is Agios Pharmaceuticals, Inc a Good Stock to Buy?
Determining whether Agios (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:AGIO share price (ISIN: US00847X1046) to enhance your trading decisions with our free investment tools and resources.
What Is the Agios Pharmaceuticals, Inc Share Price Today?
The Agios share price today is 31.80.
What Is the Stock Symbol for Agios Pharmaceuticals, Inc
The stock symbol (or 'ticker') for Agios Pharmaceuticals, Inc is "AGIO."
What Stock Exchange Does Agios Pharmaceuticals, Inc Trade On?
Agios Pharmaceuticals, Inc is listed and trades on the NASDAQ stock exchange.
Is Agios Pharmaceuticals, Inc a Good Stock to Buy?
Determining whether Agios (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.65
32.82
52 wk Range
22.24
46.00
AGIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.6532.82
52 wk Range
22.2446.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
46.25
Upside
+45.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Agios Pharm receives Investment Bank Analyst Rating Update- Investing.com
Pro
Agios Pharm receives Investment Bank Analyst Rating Update- Investing.com
Pro
Agios Pharm receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 46.25
(+45.44% Upside)
Agios Pharmaceuticals, Inc SWOT Analysis
Pyrukynd's Promise | Explore Agios's lead drug candidate Pyrukynd, potentially the next treatment for thalassemia and sickle cell disease, awaiting FDA decision by September 2025 |
Financial Fortitude | With $1.4 billion in cash and a robust financial health score, Agios stands well-positioned to fund its ambitious drug development pipeline |
Market Dynamics | Delve into Agios's competitive landscape, including challenges from Novo Nordisk's etavopivat and emerging liver safety signals for Pyrukynd |
Analyst Outlook | Analyst price targets range from $38 to $71, with an average of $56.25, suggesting potential upside from the current $30.11 trading price |
Agios Pharmaceuticals, Inc Earnings Call Summary for Q2/2026
- Agios Q2 revenue hit $44.7M, beating estimates by 68% on AQVESME sales; loss of $1.69/share missed forecast by $0.04; shares fell 3.28% premarket.
- Net loss narrowed to $100.7M from $112M YoY despite R&D rising to $100.8M and SG&A climbing 34% to $61.5M amid launch investments and licensing deals.
- Company holds ~$1B in cash; maintains 2026 PKD revenue guidance of $45-50M; expects flat operating expenses excluding $25M cevidoplenib upfront payment.
- FDA decision on mitapivat for sickle cell disease due Nov. 1; management expects no material 2026 revenue contribution from indication if approved.
- AQVESME prescriptions shifting to broader non-transfusion-dependent patients; company will discontinue prescription metrics after Q3, focus on revenue reporting.
Last Updated: 30/07/2026, 14:14
Read Full TranscriptEarnings
Latest Release
30/07/2026
EPS / Forecast
-1.69 / -1.65
Revenue / Forecast
44.74M / 26.57M
Compare AGIO to Peers and Sector
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −6.4x | −0.3x | |
PEG Ratio | 0.03 | −0.23 | 0.00 | |
Price/Book | 1.9x | 2.3x | 2.6x | |
Price / LTM Sales | 19.3x | 12.1x | 3.0x | |
Upside (Analyst Target) | 45.4% | 226.8% | 58.6% | |
Fair Value Upside | Unlock | −0.5% | 7.4% | Unlock |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Agios (NASDAQ: AGIO) Share Price Today?
The Agios stock price today is 31.80 USD.
What Stock Exchange Does Agios (AGIO) Trade On?
Agios is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Agios?
The stock symbol (also called a 'ticker') for Agios is "AGIO."
What Is the Current Agios Market Capitalisation?
As of today, Agios (NASDAQ: AGIO) market cap is 1.90B USD.
What Is Agios's (AGIO) Earnings Per Share (TTM)?
The Agios EPS is currently -7.01 (Trailing Twelve Months).
When Is the Next Agios Earnings Date?
Agios's next earnings report will be released on 29/10/2026.
Is AGIO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Agios moving averages and other technical indicators, the daily buy/sell signal for AGIO stock is Strong Sell.
How Many Times Has Agios Stock Split?
Agios has split 0 times. (See the AGIO stock split history page for full effective split date and price information.)
How Many Employees Does Agios Have?
Agios has 540 employees, based on their latest Companies House report.
What is the current trading status of Agios (NASDAQ: AGIO)?
As of 05/10/2026, Agios (AGIO) is trading at a share price of 31.80 USD, with a previous close of 31.80 USD. The stock has fluctuated within a day range of 31.65 USD to 32.82 USD, while its 52-week range spans from 22.24 USD to 46.00 USD.
What Is Agios (AGIO) Price Target According to Analysts?
The average 12-month price target for Agios is 46.25 USD, with a high estimate of 73 USD and a low estimate of 32 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +45.44% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.